RxDoctor Payments Data

Gabriel Stanescu, MD

Internal Medicine · Richmond Hts, OHNPI 1225127285

Payments from drug & device makers

$11,376in general payments, 2019–2025

Across 707 payments — averaging $16.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • AbbVie$1K
  • Boehringer Ingelheim$751
  • Abbott$698
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$11,370100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk111$1,502
AstraZeneca(2 entities)60$1,365
Pfizer77$1,188
AbbVie(2 entities)75$1,131
Boehringer Ingelheim51$751
Abbott38$698
Amgen(2 entities)38$659
Lilly USA, LLC35$511
Merck21$360
GSK16$269
E.r. Squibb & Sons, L.L.C.15$244
Astellas Pharma US Inc12$208
Amarin Pharma, Inc.11$187
Johnson & Johnson13$171
Novartis8$151
Currax Pharmaceuticals LLC13$136
Sanofi-aventis U.S. LLC8$134
Xeris Pharmaceuticals, Inc.6$113
Nestle Healthcare Nutrition Inc.6$107
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$92
Vivus LLC5$88
Genentech USA, Inc.4$80
Corcept Therapeutics4$77
Kowa Pharmaceuticals America, Inc.5$71
Takeda Pharmaceuticals U.S.A., Inc.5$71
Hikma Pharmaceuticals USA4$69
Bayer3$63
Shire North American Group Inc5$62
Mannkind Corporation4$61
Biohaven Pharmaceutical Holding Company Ltd.3$57
Aimmune Therapeutics, Inc.3$53
ANI Pharmaceuticals, Inc.2$47
Clarus Therapeutics Inc.3$45
Jazz Pharmaceuticals Inc.3$44
IBSA Pharma Inc.3$44
Biohaven Pharmaceuticals, Inc.3$41
Antares Pharma, Inc.2$39
Arbor Pharmaceuticals, Inc.2$34
Ultragenyx Pharmaceutical Inc.2$29
Neurocrine Biosciences, Inc.2$29
Lifescan, Inc.2$28
BETA Bionics, Inc.1$27
Acerus Pharmaceuticals Corporation2$27
Averitas Pharma Inc.1$21
Dynavax Technologies Corporation1$21
Dexcom, Inc.1$19
Chiesi USA, Inc.1$19
Ascendis Pharma Endocrinology Inc1$18
Verity Pharmaceuticals Inc.1$17
Recordati_rare_diseases_inc.1$16
Phathom Pharmaceuticals, Inc.3$16
Phadia US Inc.1$15
Radius Health, Inc.1$15
Amneal Pharmaceuticals LLC1$13
Nabriva Therapeutics, PLC1$12
Amryt Pharma Holdings Ltd1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,376 in reported general payments places this provider in the 90th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$129,917
Medicare patients
292
Services billed
11,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban172$180,673
FarxigaDapagliflozin Propanediol73$86,691
JardianceEmpagliflozin52$56,149
JanuviaSitagliptin Phosphate35$39,883
XareltoRivaroxaban25$29,557
TrulicityDulaglutide23$28,279
OzempicSemaglutide25$25,068
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$18,672
JanumetSitagliptin Phos/Metformin Hcl12$15,777
MounjaroTirzepatide12$12,514
MyrbetriqMirabegron11$10,469
Colchicine105$10,394
Spiriva HandihalerTiotropium Bromide14$9,454
Tresiba Flextouch U-200Insulin Degludec13$8,398
EntrestoSacubitril/Valsartan11$6,900

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$1,188$183,499201 claims
AstraZenecaFarxiga, Symbicort$1,365$90,94885 claims
Boehringer IngelheimJardiance$751$56,14952 claims
MerckJanuvia, Janumet$360$55,66047 claims
Lilly USA, LLCTrulicity, Mounjaro$511$40,79435 claims
Johnson & JohnsonXarelto$171$29,55725 claims
Novo NordiskOzempic$1,502$25,06825 claims
GSKTrelegy Ellipta$269$18,67229 claims
Astellas Pharma US IncMyrbetriq$208$10,46911 claims
NovartisEntresto$151$6,90011 claims
Sanofi-aventis U.S. LLCLantus$134$3,79413 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$13$3,791424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Richmond Hts

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →